Loughborough, England, Feb. 28, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...
Loughborough, England, Feb. 14, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...
Loughborough, England – January 10, 2022 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology...
Loughborough, England, Jan. 07, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on...
Sales in UK expected to be followed by launches across major EU territories in 2022 Loughborough, England, Dec. 07,...
Loughborough, England, Nov. 03, 2021 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing...
MiBoKo, a noninvasive glucose sensor utilizing AI mobile application, addresses a substantial multibillion-dollar market opportunity in healthcare LOUGHBOROUGH, England,...
Nemaura has previously placed order for 200,000 CGMs in anticipation of commercial ramp-up Loughborough, England – September 27, 2021...
Loughborough, England – September 21, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on...
Loughborough, England – September 17, 2021 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology...